Bibliographic Details
| Title: |
Contribution of the Paraoxonase-2 Enzyme to Cancer Cell Metabolism and Phenotypes. |
| Authors: |
Campagna, Roberto, Serritelli, Emma Nicol, Salvolini, Eleonora, Schiavoni, Valentina, Cecati, Monia, Sartini, Davide, Pozzi, Valentina, Emanuelli, Monica |
| Source: |
Biomolecules (2218-273X); Feb2024, Vol. 14 Issue 2, p208, 13p |
| Subject Terms: |
CANCER cells, VASCULAR endothelial cells, REACTIVE oxygen species, PHENOTYPES, ENZYMES |
| Abstract: |
Paraoxonase-2 (PON2) is a ubiquitously expressed intracellular protein that is localized in the perinuclear region, the endoplasmic reticulum (ER), and mitochondria, and is also associated with the plasma membrane. PON2 functions as an antioxidant enzyme by reducing the levels of reactive oxygen species (ROS) in the mitochondria and ER through different mechanisms, thus having an anti-apoptotic effect and preventing the formation of atherosclerotic lesions. While the antiatherogenic role played by this enzyme has been extensively explored within endothelial cells in association with vascular disorders, in the last decade, great efforts have been made to clarify its potential involvement in both blood and solid tumors, where PON2 was reported to be overexpressed. This review aims to deeply and carefully examine the contribution of this enzyme to different aspects of tumor cells by promoting the initiation, progression, and spread of neoplasms. [ABSTRACT FROM AUTHOR] |
|
Copyright of Biomolecules (2218-273X) is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
|
Full text is not displayed to guests. |
Login for full access.
|
